A novel role for an old target: CD45 for breast cancer immunotherapy

A novel role for an old target: CD45 for breast cancer immunotherapy

Breast cancer subtypes have not shown significant response to current immunomodulatory therapies. Although most subtypes are treatable, triple negative breast cancer (TNBC), an aggressive highly metastatic cancer, comprising 10–20% of breast cancers, remains an unmet medical need. New strategies are...

Full description

Bibliographic Details
Main Authors: Annat Raiter, Oran Zlotnik, Julia Lipovetsky, Shany Mugami, Shira Dar, Ido Lubin, Eran Sharon, Cyrille J. Cohen, Rinat Yerushalmi
Format: Article
Language:English
Published: Taylor & Francis Group 2021-01-01
Series:OncoImmunology
Subjects:
triple negative breast cancer
peripheral blood mononuclear cells
cd45
specific tumor cell killing peptide
src family of tyrosine kinases
Online Access:http://dx.doi.org/10.1080/2162402X.2021.1929725

Internet

http://dx.doi.org/10.1080/2162402X.2021.1929725

Similar Items